SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 6 of 94
Word Count: 1497
Character Count: 9519

Document Content:

only two years of audited financial statements and only two years of related management’s discussion and analysis of financial condition and results of operations disclosure; exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”); ● reduced disclosure about executive compensation arrangements in our periodic reports, registration statements, and proxy statements; and ● exemptions from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements. particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock.

addition, the JOBS Act permits emerging growth companies to take advantage of an extended transition period to comply with new or revised
accounting standards applicable to public companies. We are not choosing to “opt out” of this provision. We will remain an
emerging growth company until the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.235
billion, (ii) the date on which we first qualify as a large accelerated filer under the rules of the Securities and Exchange Commission
(the “SEC”), (iii) the date on which we have, in any three-year period, issued more than $1.0 billion in non-convertible
debt securities, and (iv) the last day of the fiscal year following the fifth anniversary of the completion of this offering.

Implications
of Being a Smaller Reporting Company

Following
this offering, we will be a “smaller
reporting company” as defined in Rule 12b-2 under the Exchange Act. We may take advantage of certain of the scaled disclosures
available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock
held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues
are less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates
is less than $700 million measured on the last business day of our second fiscal quarter.

Corporate
Information

We are currently
a Delaware corporation. Our predecessor, CHF Technologies,
Inc., was incorporated under the laws of the State of California on October 15, 2003. On June 8, 2012, we incorporated BioVentrix, Inc.
under the laws of the State of Delaware, which subsequently merged into CHF Technologies, Inc., with BioVentrix, Inc. as the surviving
corporation in the merger. Our principal executive office is located at 120 Forbes Blvd., Suite 125, Mansfield, MA 02048. Our telephone
number is (925) 290-1000 and our website is www.bioventrix.com. Information contained on, or available through, our website
does not constitute part of, and is not deemed incorporated by reference into, this prospectus, and investors should not consider any
such information as part of this prospectus.

THE
OFFERING

Common
Stock Offered by Us shares
of common stock on a firm commitment basis (or shares of common stock if the underwriters exercise their over-allotment option in
full).

Common
Stock Outstanding Prior to This Offering 5,723,895
shares of common stock outstanding as of March 31, 2026.

Common
Stock to Be Outstanding Immediately After Completion of This Offering (1) shares
of common stock (or            shares of common stock if the underwriters
exercise their over-allotment option in full).

Over-allotment
Option We
have granted the underwriters a 30-day option to purchase up to an additional
shares of our common stock at the initial public offering price, less underwriting discounts and commissions, solely to cover over-allotments,
if any.

Use
of Proceeds We
estimate that the net proceeds to us from this offering, after deducting the underwriting
discounts and estimated offering expenses payable by us, will be approximately $
million, or approximately $          million
if the underwriters exercise their over-allotment option in full, based on the assumed initial
public offering price of $         per share.

The
net proceeds received by us from this offering will be used primarily to fund the RELIVE clinical trial and the associated manufacturing
activities required to support such trial. The remaining portion of the net proceeds will be used to fund working capital and general
and administrative expenses. See “ Use of Proceeds .”

Underwriters’
Warrants The
registration statement of which this prospectus is a part also registers the offer and sale of common stock purchase warrants
to be issued to the underwriters (the “Underwriters’ Warrant”) to purchase shares of our common stock
(or 5% of the shares of common stock sold in this offering), including any shares of common stock sold pursuant to the exercise of
the underwriters’ over-allotment option, and the shares of our common stock issuable upon exercise of the Underwriters’
Warrants. The Underwriters’ Warrants are being issued to the underwriters as a portion of the underwriting compensation
payable in connection with this offering. The Underwriters’ Warrants are exercisable at any time, and from time to time,
in whole or in part, from the first day of the seventh month after the closing of this offering, to the date that is five years from
the date of commencement of sales in this offering, at an exercise price equal to the initial public offering price of the shares
of common stock. Please see “ Underwriting — Underwriters’ Warrants ” for further information.

Listing We
have applied to have our common stock listed on Nasdaq. No assurance can be given that our listing will be approved by
Nasdaq or that a trading market will develop for our common stock. We will not proceed with this offering in the event that our common
stock is not approved for listing on Nasdaq.

Proposed
Nasdaq symbol “BVXX”

Risk
Factors Investing
in our common stock is speculative and involves a high degree of risk . See “ Risk Factors ” beginning on
page 10 and the other information in this prospectus for a discussion of the factors you should consider carefully before you decide
to invest in our common stock.

Lock-Up In
connection with this offering, we, our executive officers, directors, and our existing stockholders have agreed not to offer, sell
or otherwise transfer or dispose of any shares of our capital stock for a period of six (6) months following the closing of this
offering. See “ Underwriting ” beginning on page 116 for more information.

Transfer
Agent The
transfer agent and registrar for our common stock is Issuer Direct Corporation.

(1)	The
number of shares of our common stock to be outstanding upon completion of this offering will be
shares assuming no exercise of the over-allotment by the underwriters, which is based on 5,723,865 shares of our common stock
outstanding as of March 31, 2026, and 7,943,927 shares of common stock being issued upon the closing of this
offering in connection with the conversion of: (i) 1,302,950 shares of our existing Series A Preferred Stock into 1,302,950
shares of common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00) and
(ii) $12,797,898 of our existing convertible notes into 6,640,977 shares of our common stock (assuming an initial public
offering price of at least $10.00 and an assumed conversion price of $10.00), and excludes, as of the date of this prospectus:

●	shares
of common stock issuable upon the exercise of the Underwriters’ Warrants;

●	1,025,500 shares of our common stock reserved for
issuance under stock option agreements issued pursuant to the BioVentrix 2024 Equity Incentive Plan (the “2024 Plan”);
and

shares of our common stock (which is equal to         % of our issued and outstanding common
stock immediately after the consummation of this offering) reserved for future issuance under the BioVentrix, Inc. 2026 Equity Incentive
Plan (the “2026 Plan”), which will become effective as of the closing of this offering.

Unless
otherwise indicated, this prospectus reflects and assumes (i) no exercise by the underwriters of their over-allotment option and (ii)
no exercise of the outstanding stock options described above.

SUMMARY
OF CONSOLIDATED FINANCIAL INFORMATION

The following tables set
forth summary financial and other data for the periods ended and at the dates indicated below. Our summary financial information for
the three months ended March 31, 2026 and 2025 and as of March 31, 2026 and 2025 has been derived from our unaudited interim
condensed financial statements included elsewhere in this prospectus. Our summary financial information for the years ended December
31, 2025 and 2024 and as of December 31, 2025 and 2024 has been derived from our audited financial statements included in this
prospectus. The financial data set forth below should be read in conjunction with “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” and the financial statements and notes thereto included elsewhere in this
prospectus.